Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan

Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and
                            Policy, to Join Mylan

PR Newswire

PITTSBURGH, April 30, 2013

PITTSBURGH, April 30, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that it has appointed Deborah M. Autor as senior vice president,
Strategic Global Quality and Regulatory Policy. Autor joins Mylan from the
U.S. Food and Drug Administration (FDA), where she served for 11 years, most
recently as deputy commissioner for Global Regulatory Operations and Policy.
At Mylan, Autor will focus on further advancing Mylan's efforts to lead the
industry in establishing one global quality standard for pharmaceutical
products and expanding the world's access to high quality medicine.

Mylan CEO Heather Bresch commented, "We are thrilled to welcome Deb to Mylan
in this unique role and believe that her experience, dedication and commitment
to advancing global quality standards at FDA align with Mylan's commitment to
ensuring one high quality standard for our products wherever they are made.
Deb's insights into the challenges of globalization to the health care sector
will be extremely valuable as we continue to seek to raise the bar on quality
standards for the industry around the world. Our goal is to ensure that anyone
taking medicine anywhere can be confident in the quality standards used to
produce it."

Mylan President Rajiv Malik added, "Mylan's reputation for quality has
distinguished our company since its founding more than 50 years ago and helped
fuel our growth into a global pharmaceutical leader. We believe Deb's decision
to join Mylan speaks to the culture of quality she has seen embedded within
our organization and believe that Deb can help further differentiate Mylan
from its competitors in terms of quality, integrity and service as we seek to
provide the world's 7 billion people with access to high quality medicine."

Autor commented, "Mylan has been a leading advocate for ensuring one quality
standard, both internally and externally, as evidenced by the company's active
role in the development and passage of the FDA Safety and Innovation Act, or
FDASIA. I am very excited to be joining an organization whose people
demonstrate such extraordinary passion and commitment to quality and access to
medicine. I look forward to contributing to Mylan's continued leadership on
quality – both from an operational and policy perspective."

Most recently, Autor oversaw the Office of Regulatory Affairs and the Office
of International Programs at FDA, with responsibility for 4,400 employees. In
this role, she led the implementation of FDA's strategy for addressing the
challenges of globalization and import safety. Under Autor's leadership, her
organization made great strides in becoming more data-driven, strategic and
risk-based, moving closer to its vision of a strong global product safety net
in which all food is safe, all medical products are safe and effective, and
the public health is advanced and protected.

Prior to assuming the role of deputy commissioner, Autor served for five years
as director of the Office of Compliance in FDA's Center for Drug Evaluation
and Research (CDER). In that role, she led policymaking and enforcement for
key public health programs for drugs, including current good manufacturing
practices, human-subject protection and bioresearch monitoring, marketed
unapproved drugs, pharmaceutical import and export, Internet and health fraud,
over-the-counter monograph compliance, adverse-event reporting, registration
and listing, and drug recalls. Under Autor's leadership, CDER's Office of
Compliance worked to minimize consumers' exposure to unsafe, ineffective and
poor quality drugs.

Autor also served in the CDER Office of Compliance as a senior advisor and as
associate director for Compliance Policy. Prior to joining FDA, for seven
years, Autor represented the agency as a litigator at the U.S. Department of
Justice (DOJ).

In recognition of her contributions to public health, Autor was awarded the
2011 Meritorious Executive Presidential Rank Award, the 2011 Food and Drug Law
Institute's Distinguished Service and Leadership Award, and was a 2010
finalist for the prestigious Service to America Medal. Autor obtained her B.A.
from Barnard College of Columbia University and her J.D. magna cum laude from
Boston University School of Law, where she was an article editor for the
Boston University Law Review.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), 724.514.1968, or Kris King (Investors),
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.